Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AZNCF AstraZeneca	$134.75 -1.8%	$144.01	$120.64 ▼ $175.00	N/A	N/A	2,122 shs	1,084 shs
CMOPF Cosmo Pharmaceuticals	C$55.00	C$65.85	C$55.00 ▼ C$95.00	N/A	N/A	350 shs	N/A
CSPCY CSPC Pharmaceutical Group	C$3.13 -0.8%	C$2.57	C$2.15 ▼ C$3.82	N/A	N/A	30,277 shs	516 shs
KYKOF Kyowa Kirin	$14.75	$13.88	$12.32 ▼ $22.21	N/A	N/A	326 shs	N/A

10 Stocks Set to Soar in Spring 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AZNCF AstraZeneca	0.00%	-3.61%	-8.63%	-3.00%	-7.13%
CMOPF Cosmo Pharmaceuticals	0.00%	0.00%	-12.41%	-22.21%	-31.25%
CSPCY CSPC Pharmaceutical Group	0.00%	+11.79%	+20.85%	+37.28%	-5.75%
KYKOF Kyowa Kirin	0.00%	0.00%	0.00%	-0.34%	-16.34%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AZNCF AstraZeneca	0.1199 of 5 stars	0.0	0.0	1.7	0.0	1.2	0.8	0.0
CMOPF Cosmo Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CSPCY CSPC Pharmaceutical Group	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
KYKOF Kyowa Kirin	0.3926 of 5 stars	0.0	0.0	1.7	0.0	1.6	0.0	1.3

Compare Analyst Forecasts

Company	Consensus Rating	Consensus Price Target	% Upside from Current Price
AZNCF AstraZeneca	N/A	N/A	N/A
CMOPF Cosmo Pharmaceuticals	N/A	N/A	N/A
CSPCY CSPC Pharmaceutical Group	N/A	N/A	N/A
KYKOF Kyowa Kirin	N/A	N/A	N/A

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AZNCF AstraZeneca	N/A	N/A	N/A	N/A	N/A	N/A
CMOPF Cosmo Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A
CSPCY CSPC Pharmaceutical Group	N/A	N/A	N/A	N/A	N/A	N/A
KYKOF Kyowa Kirin	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AZNCF AstraZeneca	N/A	$0.82	165.13	∞	N/A	N/A	N/A	N/A	4/29/2025 (Estimated)
CMOPF Cosmo Pharmaceuticals	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
CSPCY CSPC Pharmaceutical Group	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
KYKOF Kyowa Kirin	N/A	$34.33	0.43	∞	N/A	N/A	N/A	N/A	5/1/2025 (Estimated)

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AZNCF AstraZeneca	$2.80	2.08%	N/A	343.14%	N/A
CMOPF Cosmo Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CSPCY CSPC Pharmaceutical Group	N/A	N/A	N/A	N/A	N/A
KYKOF Kyowa Kirin	$19.94	135.18%	N/A	58.08%	N/A

Latest KYKOF, AZNCF, CMOPF, and CSPCY Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
2/6/2025	AZNCF AstraZeneca		$2.10		2/19/2025	2/21/2025	3/24/2025

(Data available from 1/1/2013 forward)

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AZNCF AstraZeneca	40.87%
CMOPF Cosmo Pharmaceuticals	N/A
CSPCY CSPC Pharmaceutical Group	N/A
KYKOF Kyowa Kirin	10.28%

Insider Ownership

Company	Insider Ownership
AZNCF AstraZeneca	N/A
CMOPF Cosmo Pharmaceuticals	N/A
CSPCY CSPC Pharmaceutical Group	N/A
KYKOF Kyowa Kirin	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AZNCF AstraZeneca	83,500	N/A	N/A	Not Optionable
CMOPF Cosmo Pharmaceuticals	319	N/A	N/A	Not Optionable
CSPCY CSPC Pharmaceutical Group	23,500	N/A	N/A	Not Optionable
KYKOF Kyowa Kirin	5,974	N/A	N/A	Not Optionable

KYKOF, AZNCF, CMOPF, and CSPCY Headlines

Recent News About These Companies

Fierce Pharma Asia—The latest on Trump's tariffs; Leqembi's EU approval; Kyowa Kirin's biologics plant

April 20, 2025 | fiercepharma.com

Kyowa Kirin constructs drug manufacturing facility in Japan

April 14, 2025 | pharmaceutical-technology.com

As work on massive US plant continues, Kyowa Kirin wraps up construction of $118M biologics plant in Japan

April 11, 2025 | fiercepharma.com

35-YEAR INDUSTRY-ACADEMIC PARTNERSHIP YIELDING GROUNDBREAKING ADVANCES FOR SCIENCE AND PATIENTS RENEWS FOR ANOTHER THREE YEARS BETWEEN LA JOLLA INSTITUTE FOR IMMUNOLOGY AND KYOWA KIRIN

April 3, 2025 | prnewswire.com

Amgen And Kyowa Kirin's Rocatinlimab Reduces Eczema Severity In Phase 3 Study

March 12, 2025 | benzinga.com

Kyowa Kirin, Amgen’s rocatinlimab ignites positive response in Rocket study

March 11, 2025 | bioworld.com

Amgen & Kyowa Kirin positive results from rocatinlimab phase 3 IGNITE study in adults with moderate to severe atopic dermatitis

March 11, 2025 | pharmabiz.com

Amgen and Kyowa Kirin’s rocatinlimab trial for atopic dermatitis meets endpoints

March 10, 2025 | msn.com

Amgen, Kyowa Kirin’s rocatinlimab trial for atopic dermatitis meets endpoints

March 10, 2025 | finance.yahoo.com

Amgen, Kyowa announces new results from ongoing ROCKET Phase 3 study

March 10, 2025 | markets.businessinsider.com

Jefferies Remains a Buy on Kyowa Kirin Co (KYKOF)

March 9, 2025 | markets.businessinsider.com

J.P. Morgan Sticks to Its Hold Rating for Kyowa Kirin Co (KYKOF)

March 8, 2025 | markets.businessinsider.com

BRIEF—Kyowa Kirin and Sandoz permitted partial change of rituximab biosimilar

March 7, 2025 | thepharmaletter.com

Kyowa Kirin Announces Late-Breaking Abstract Presentation at the American Academy of Dermatology Annual Meeting 2025

February 26, 2025 | prnewswire.com

Kura Oncology CEO Troy Wilson to Speak at Upcoming Investor Conferences in March 2025

February 25, 2025 | quiverquant.com

Bristol Myers Squibb, Kyowa Kirin layoffs hit 119 in New Jersey amid separate restructuring campaigns

February 6, 2025 | fiercepharma.com

Kura, Kyowa Kirin announce KOMET-001 results, FDA feedback for trial designs

February 5, 2025 | markets.businessinsider.com

BioKyowa facility among businesses sold to Chinese amino acids supplier

February 3, 2025 | semissourian.com

Kyowa Kirin and Swixx BioPharma announce expansion of access to POTELIGEO® (mogamulizumab) for adults living with mycosis fungoides or Sézary syndrome in Central and Eastern Europe

January 30, 2025 | businesswire.com

AlphaMeld Corporation Expands Collaboration with Kyowa Kirin for Enterprise-Wide Access to Drug Discovery Platform

January 28, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KYKOF, AZNCF, CMOPF, and CSPCY Company Descriptions

AstraZeneca OTCMKTS:AZNCF

$134.75 -2.49 (-1.81%)

As of 04/25/2025 12:29 PM Eastern

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Cosmo Pharmaceuticals OTC:CMOPF

C$55.00 0.00 (0.00%)

As of 04/25/2025

Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, focuses on the development and commercialization products for gastroenterology, endoscopy, dermatology, and healthtech worldwide. The company offers Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Lumeblue (methylene blue MMX), a diagnostic drug to enhance pre-cancerous and cancerous detection of colorectal lesions during colonoscopy; Uceris/Cortiment, an oral tablet formulation which delivers budesonide directly to the lumen of the colon; Aemcolo/Relafalk, a GI antibiotic with MMX® technology and is approved for the treatment of travellers' diarrhoea; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Eleview, a medical device, which enables the safer and faster removal of colonic lesions; and GI Genius, a system that uses artificial intelligence to detect colorectal polyps during colonoscopy. It is also in the development of Breezula (clascoterone), a novel androgen receptor inhibitor that targets androgen receptors in the scalp, currently expecting phase III trials; Rifamycin SV MMX IBS-D, a formulation to treat colonic infections and irritable bowel syndrome with diarrhoea, currently completed phase II proof of concept clinical trials; CB-03-10 (cortexolone 17 -valerate-21-propionate), an oral androgen receptor antagonist for treatment solid tumors, currently under phase I studies; and CB-01-33 (colesevelam) for the treatment of bile acid diarrhea, currently under preclinical studies. The company has development, distribution, and licensing agreements with Bausch Health, Ferring, China Medical System Holdings Limited, Medtronic, Parmascience Inc., RedHill Biopharma Ltd., Dr. Falk Pharma, Sun Pharmaceutical Industries Ltd., 3SBio, InfectoPharm, and Hyphens Pharma International Limited. Cosmo Pharmaceuticals N.V. was founded in 1997 and is headquartered in Dublin, Ireland.

CSPC Pharmaceutical Group OTCMKTS:CSPCY

C$3.13 -0.03 (-0.79%)

As of 04/25/2025 12:08 PM Eastern

CSPC Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People's Republic of China, other Asian regions, North America, Europe, and internationally. The company operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. It provides NBP soft capsules and injections for acute ischemic stroke; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Enxi to treat adult idiopathic Parkinson's disease; Duomeisu for lymphoma, multiple myeloma, ovarian and breast cancers, and other malignant tumors; Jinyouli to prevent leucopenia and infection induced by chemotherapy; and Keaili for breast cancer. The company also offers Shuluoke, Nuomoling, Weihong, and Xinweihong for various infections; Xuanning for hypertension; Encun to prevent atherosclerotic thrombosis events; Qixiao to treat upper respiratory tract infection; Linmeixin and Shuanglexin for diabetes; Gubang and Gubangjia to treat osteoporosis in postmenopausal women; and Gaoshunsong for arthritis, osteoarthritis, ankylosing spondylitis, frozen shoulder, bursuitis, tenosynovitis, acute gout, dysmenorrhea, toothache and postoperative pain, low back pain, sprain, strain, and other soft tissue injuries. In addition, it provides Debixin for various ulcer; Qimaite for acute and chronic pains; antibiotics, vitamin C, and caffeine APIs; functional food and glucose products; and healthcare services. The company has a strategic partnership with Pfizer Inc. to launch a local brand of the COVID-19 oral therapeutic treatment Nirmatrelvir/Ritonavir in China. The company was formerly known as China Pharmaceutical Group Limited and changed its name to CSPC Pharmaceutical Group Limited in March 2013. CSPC Pharmaceutical Group Limited was incorporated in 1992 and is headquartered in Shijiazhuang, the People's Republic of China.

Kyowa Kirin OTCMKTS:KYKOF

$14.75 0.00 (0.00%)

As of 04/25/2025

Kyowa Kirin Co., Ltd. engages in the research, development, manufacturing, marketing, and import/export of pharmaceuticals for oncology, nephrology, central nervous system, and immunology therapeutic areas in Japan, the United States, rest of the Americas, Europe, Asia, and internationally. Its products include ALLELOCK, an antihistamine agent for patients with various types of allergies; CONIEL, a calcium channel blocker for hypertension and angina pectoris; Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; ESPO, a glycoprotein and human erythropoietin; NESP, an erythropoiesis stimulating agent; and GRAN, a human colony-stimulating factor. The company also develops GRAN /Peglasta/Neulasta for chemotherapy-induced febrile neutropenia; LUMICEF, a biological treatment for moderate to severe plaque psoriasis; Moventig, a mu-opioid receptor antagonist for the treatment of opioid induced constipation; Nouriast/ Nourianz, an adenosine receptor antagonist for Parkinson's disease; and ORKEDIA, an oral calcimimetics agent. In addition, it offers POTELIGEO, a humanized monoclonal antibody for CC chemokine receptor 4; REGPARA for the treatment of secondary hyperparathyroidism; and Romiplate/Nplate, a genetically recombinant protein that produces platelet through the stimulation of thrombopoietin receptors. Kyowa Kirin Co., Ltd. has an agreement with Amgen Inc. to jointly develop and commercialize KHK4083, an anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in June 2019. The company was incorporated in 1949 and is headquartered in Tokyo, Japan. Kyowa Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time